Zacks Investment Research cut shares of Mesoblast Limited (NASDAQ:MESO) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Several other equities analysts also recently commented on MESO. Maxim Group set a $14.00 target price on shares of Mesoblast Limited and gave the stock a buy rating in a research report on Wednesday, August 16th. Cantor Fitzgerald restated a buy rating on shares of Mesoblast Limited in a report on Wednesday, August 23rd. ValuEngine cut shares of Mesoblast Limited from a hold rating to a sell rating in a report on Friday, September 15th. BidaskClub cut shares of Mesoblast Limited from a hold rating to a sell rating in a report on Wednesday, July 12th. Finally, Credit Suisse Group set a $11.00 price target on shares of Mesoblast Limited and gave the company a hold rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $13.14.
Mesoblast Limited (MESO) opened at $5.13 on Wednesday. Mesoblast Limited has a 1 year low of $4.07 and a 1 year high of $12.50.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Lowers Mesoblast Limited (MESO) to Hold” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.com-unik.info/2017/11/05/zacks-investment-research-lowers-mesoblast-limited-meso-to-hold.html.
About Mesoblast Limited
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Mesoblast Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mesoblast Limited and related companies.